Please login to the form below

Not currently logged in
Email:
Password:

Merck's Saphris cleared for new uses

Merck has won US Food and Drug Administration approval of new indications for its atypical antipsychotic Saphris

Merck has won US Food and Drug Administration (FDA) approval of new indications for its atypical antipsychotic Saphris (asenapine).

The sublingual tablets may now be marketed for the treatment of schizophrenia in adults, as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, and as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.

Saphris won its initial US approval in mid-August of last year for the acute treatment of schizophrenia in adults and as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults.

Earlier this month, the drug, which Merck markets as Sycrest outside the US, won approval throughout the EU for treating moderate to severe manic episodes in adult patients with bipolar I disorder. However, European authorities declined to approve the drug as a treatment of schizophrenia.

Saphris was acquired in late-stage clinical development by Schering-Plough as part of the company's 2007 merger with Organon International. Merck and Schering-Plough merged last year.

Merck has not yet reported sales figures for the recently launched drug.

8th September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics